Medtronic (MDT +0.83%) has raised its dividend payouts annually for 49 consecutive years. In other words, the medical device company is just one more year and one more hike away from becoming one of just a few dozen Dividend Kings -- publicly traded companies with at least 50 consecutive years of dividend growth.
However, this status alone may not necessarily indicate that it's a strong buy for income investors. Let's take a look at other factors to assess whether this dividend growth stock can produce the type of steady, solid total returns associated with such kingly status.
Image source: Getty Images
Dividend Kings status is well within reach for Medtronic If Medtronic raises its dividend again in June 2027, the company will officially attain Dividend King status. Based on the details, hitting this appears well within reach, if not a near certainty. For one, based on estimated earnings for the current fiscal year, Medtronic has a payout ratio of just 45%.
Premium Feature
Moneyball Superscore
75/100
Today's Change
(
0.83
%) $
0.77
Current Price
$
93.16
True, in March, Medtronic spun off its diabetes products business as a new public company, MiniMed Group (MMED -2.08%). For now, Medtronic holds around a 90% stake in MiniMed, but Medtronic CEO Geoff Martha says the company plans to eventually reduce that position to zero. However, don't assume this will severely affect Medtronic's dividend growth bandwidth once it happens.
It's still unclear whether Medtronic plans to complete the sale of that stock by the end of 2026, as it continues to include MiniMed's results in its full-year forecasts. Also note that MiniMed reported negative cash flow during the fiscal year that ended in April 2026. If Medtronic completes its divestiture of MiniMed while it remains unprofitable, it could increase Medtronic's overall cash flow, enabling a further dividend increase.
Not only that, on top of recent improving growth, forecasts call for a further growth resurgence. Finally, given that Medtronic has slowed the pace of its dividend growth in recent years, with the latest increase just 1.4%, it could easily implement another modest dividend increase next June without overextending itself, thereby clinching Dividend King status.
While Medtronic doesn't face any significant hurdles to becoming a Dividend King, it's unclear whether it is a strong choice for investors seeking portfolio income over price appreciation. If the company's anticipated growth resurgence pans out, it may lead to faster dividend growth in the coming years.
However, in the meantime, Medtronic may have to maintain its policy of low dividend growth to fund its main growth drivers, such as robotic surgery and cardiac products. Medtronic has also been making acquisitions, particularly of cardiac products companies, to boost growth. This, too, could limit how much Medtronic can devote to growing its quarterly cash payouts.
That said, for investors seeking both portfolio income and capital growth, it could be a solid opportunity in the coming years. For now, investors can collect a payout that yields about 3.1% at the current share price. In the years ahead, if earnings growth accelerates, shares could surge in line with earnings.
I wouldn't rule out the possibility of the market rerating the stock higher, but keep in mind that with Medtronic trading at around 15.5 times estimated earnings for the fiscal year ending April 2027, in line with other medical device stocks such as Boston Scientific and GE Healthcare, I wouldn't assume too much potential for multiple expansion.
Medtronic zvýšil výhled organického růstu tržeb pro fiskální rok 2027 na 7,25 % až 7,75 % po 13,7% růstu v 1. čtvrtletí. Rizika ale zůstávají kvůli maržím, kurzu a exekuci.
Key Takeaways Medtronic's organic growth broadened across Cardiovascular, Medical Surgical and Neuroscience.Medtronic raised fiscal 2027 organic revenue growth guidance to 7.25%-7.75%.Medtronic faces margin sensitivity, currency exposure and portfolio execution demands. Medtronic plc (MDT - Free Report) is entering fiscal 2027 with broader revenue growth, higher earnings guidance and a valuation near its historical norm. Those positives improve the investment case, but they do not remove questions around margins, foreign exchange and execution.
The stock therefore sits between improving fundamentals and still-elevated operating risk. Investors have more evidence that growth is becoming durable, yet the current setup still argues for selectivity rather than an aggressive stance.
Medtronic’s Growth Case Is Getting StrongerFiscal 2027 first-quarter organic revenue increased 13.7%, although the extra selling week contributed about 670 basis points to growth. Cardiovascular rose 18.9% organically, Medical Surgical gained 10.2% and Neuroscience advanced 9.3%, showing that performance was not confined to one franchise.
Cardiac Ablation Solutions remained a major driver, rising 88% worldwide, while Cardiac Rhythm Management, Cranial & Spinal Technologies and Surgical also delivered solid growth. Management raised full-year organic revenue growth guidance to 7.25%-7.75% from 6.75%-7.25%, reinforcing expectations for a stronger fiscal year.
Image Source: Zacks Investment Research
MDT Still Faces Margin and Execution RisksThe margin path remains less straightforward. Product mix was unfavorable by 50 basis points in the first quarter, mainly because of Diabetes and Cardiac Ablation Solutions. Adjusted operating margin expanded only 10 basis points to 23.7% as Medtronic continued spending on commercialization, acquisitions and growth platforms.
Tariffs were a slight headwind because payments were largely offset by refunds, but management has not assumed future refunds in its outlook. Foreign exchange is expected to create a $50-$150 million revenue headwind for fiscal 2027. The planned MiniMed separation before fiscal year-end adds another execution variable.
Medtronic Trades Near Its Five-Year Median MultipleMedtronic trades at 15.42X forward 12-month earnings, close to its five-year median of 15.72X. That level is below the cited sub-industry multiple of 16.92X, the Medical sector’s 21.30X and the S&P 500’s 20.10X.
Image Source: Zacks Investment Research
The discount offers some valuation support, but it is not large enough to make execution concerns irrelevant. With the stock already up 17.4% in the past three months, further upside may depend more on sustained growth and margin delivery than on multiple expansion.
MDT’s Earnings Outlook Supports a Hold-or-Buy DebateAdjusted first-quarter earnings of $1.45 per share increased 15.1% year over year and beat the Zacks Consensus Estimate by 4.3%. Medtronic raised fiscal 2027 adjusted earnings guidance to $5.94-$6.00, while the consensus estimate is $5.96 for the current fiscal year and $6.36 for fiscal 2028.
Competition remains active in key growth markets. Abbott Laboratories (ABT - Free Report) reported 13.4% comparable Electrophysiology growth in second-quarter 2026, while Boston Scientific Corporation (BSX - Free Report) posted 9.1% organic Electrophysiology growth in the same period, underscoring the intensity around cardiac ablation and related technologies.
Medtronic’s Scores Favor SelectivityThe bottom line is that Medtronic’s operating picture has improved enough to support continued interest, but the risk-reward balance is not one-sided. Better revenue breadth and a firmer earnings outlook are offset by margin sensitivity, currency exposure and portfolio execution demands.
The stock currently carries a Zacks Rank #3 (Hold). Its Value Score of B and VGM Score of B are favorable, while the Growth Score of C and Momentum Score of C are more neutral. Because Zacks Style Scores are designed to complement the Zacks Rank, that combination supports a patient stance while investors watch whether stronger growth translates into more durable earnings and margin progress.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Medtronic na konferenci uvedl, že růst táhnou AI, robotika a ablace; ablační byznys už překonal dřívější cíl 2 miliard USD výnosů. Firma také čeká, že Hugo letos překročí 50 000 kumulativních výkonů.
Medtronic’s Stars Are Aligning for a Price RecoveryMedtronic NYSE: MDT executives said the medical device maker is seeing accelerating growth across major franchises and emerging product categories, supported by innovation in artificial intelligence, robotics and new therapies.
Speaking at the Wells Fargo Healthcare Conference, Chairman and Chief Executive Officer Geoff Martha said medical technology is benefiting from innovations that can improve outcomes while potentially lowering costs and expanding patient access. He described AI and robotics as “force multipliers” that enable the company to diagnose conditions earlier and personalize treatment at scale.
Get Medtronic alerts:
Medtronic Bottoms, Healthy Rebound AheadMartha said Medtronic’s AI applications are centered on structured physiological, device and procedure data rather than broad large-language-model applications. He pointed to GI Genius, the company’s AI-supported colonoscopy technology, as an example. In the U.S., he said the technology is becoming a standard of care after clinical trials found that 25% to 50% of polyps could be missed even at leading centers. He also cited its use in India, where less-experienced physicians were able to achieve diagnostic results comparable to those in the U.S.
Limited ACA Exposure, China Stabilization Addressing concerns around healthcare policy changes, Martha said Medtronic has limited exposure to Affordable Care Act-related programs. He said the company’s procedure mix is largely acute rather than elective, with approximately two-thirds of its payer mix tied to Medicare, 25% to commercial insurance and less than 10% to Medicaid. ACA-related programs account for less than 1% of Medtronic’s global revenue, he said.
3 Reasons Analysts Love DexComIn China, Chief Financial Officer Thierry Piéton said Medtronic’s revenue exposure has fallen to between 5% and 6% following volume-based procurement, or VBP, changes. However, he said the company believes the impact of VBP is now largely behind it and that China has returned to a more normal operating environment. Martha said Medtronic remains committed to the country, which he characterized as a profitable growth market as the government expands access to higher-end healthcare.
First-Quarter Growth and Franchise Performance Piéton said Medtronic reported first-quarter growth of 13.7% including an extra week in the period, or about 7% after adjusting for that extra week. He said the company’s large established franchises are growing faster than in prior periods, while several newer businesses could provide additional expansion.
Cardiac rhythm management: Revenue rose 15% including the extra week, or about 9% on an adjusted basis, driven by EV-ICD, conduction system pacing and leadless pacemaker technology, according to Piéton. Spine: Piéton said the Stealth AXiS platform has helped Medtronic offer navigation, visualization and robotic-assistance tools alongside implants, supporting customer retention and pricing. Surgical: The surgical business performed well, including acute care and monitoring, he said. High-growth opportunities: Piéton identified cardiac ablation, Symplicity renal denervation for hypertension, Altaviva for urinary incontinence and Hugo surgical robotics as four potentially multibillion-dollar opportunities. Martha said Medtronic has effectively doubled its investment in innovation in recent years when both internal research and development and external investments, including venture investments and acquisitions, are considered. He said the company’s growth is diversified by geography, business line and a mix of organic and inorganic investment.
Cardiac Ablation and Robotics Expansion Cardiac ablation was a notable driver, with Martha describing the business as exceeding the company’s earlier expectation of reaching $2 billion in sales. Piéton said the market is growing at a mid-teens rate, or around 15%, and Medtronic expects to grow at more than 2.5 times the market rate for the full fiscal year. He said the company grew its capital-equipment installed base by 40% in the fourth quarter and by 35% sequentially in the first quarter, which should support future catheter demand.
Medtronic’s Sphere-9 catheter is currently a major contributor to ablation growth, Piéton said. The company has launched Sphere-360 in Europe and is conducting U.S. clinical trials. Martha said the company recently completed enrollment in the Sphere-360 trial, which includes a 12-month follow-up before submission.
On surgical robotics, Martha discussed Medtronic’s $700 million investment and distribution agreement with Cornerstone, which provides rights to the Sentire surgical robot in 50 countries outside the U.S. He said the deal broadens Medtronic’s offering in international markets, where hospitals and health systems may seek alternatives tailored to local needs and pricing.
Martha said Hugo, Medtronic’s surgical robotics platform, is focused on developed markets. The company expects to surpass 50,000 cumulative procedures and reach approximately 250 cumulative installed systems globally by year-end. Piéton said Hugo is already contributing to surgical-business growth, though the company did not provide specific revenue figures. Martha said Hugo has reached 99% uptime in the U.S. following software updates and refinements during its controlled launch.
Pipeline, Portfolio and Investor Day Martha said Medtronic sees renal denervation as a future billion-dollar product opportunity. He said the company is working to expand payer coverage and referral pathways for its hypertension therapy after a national U.S. coverage decision. He also said Medtronic plans more direct-to-consumer marketing in selected cities beginning in the fall.
Medtronic continues to evaluate tuck-in acquisitions, Piéton said, noting that the company has announced approximately $2.7 billion to $2.8 billion in deals over the last 12 months, compared with roughly $400 million to $500 million annually in the preceding six or seven years. He said the company intends to balance acquisition-related dilution with overhead leverage and improved gross margins.
The company also reiterated its intention to separate its MiniMed diabetes business. Piéton said Medtronic’s guidance assumes MiniMed remains consolidated for the full fiscal year, and that the ultimate earnings-per-share impact of a separation would depend on timing. He said MiniMed’s business performance has improved, but the intent to separate the business has not changed.
Medtronic plans to provide additional details on its growth outlook, new drivers and long-term financial framework at an Investor Day in December in Charlotte, North Carolina. Martha said the event will include demonstrations of the company’s robotics and digital technology ecosystems as well as physician perspectives.
About Medtronic (NYSE:MDT)Medtronic plc is a global medical technology company that develops, manufactures and sells devices and therapies used to diagnose and treat a broad range of medical conditions. Its products are designed for hospitals, physicians and patients across areas including cardiac care, diabetes, neurological disorders, spinal conditions and surgical procedures.
The company's portfolio includes pacemakers, implantable cardioverter-defibrillators, cardiac ablation systems, heart valves, neurostimulation systems, implantable pumps, spinal implants and surgical technologies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Medtronic Right Now?Before you consider Medtronic, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.
While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
AXQ Capital LP lifted its position in shares of Medtronic PLC (NYSE:MDT – Free Report) by 109.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 28,303 shares of the medical technology company’s stock after purchasing an additional 14,816 shares during the quarter. AXQ Capital LP’s holdings in Medtronic were worth $2,214,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently bought and sold shares of MDT. Monetary Solutions Ltd purchased a new stake in shares of Medtronic during the 4th quarter valued at about $27,000. Anfield Capital Management LLC boosted its holdings in Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 230 shares during the period. Acumen Wealth Advisors LLC acquired a new stake in Medtronic in the fourth quarter valued at approximately $29,000. Imprint Wealth LLC purchased a new stake in shares of Medtronic during the third quarter valued at approximately $31,000. Finally, Basepoint Wealth LLC purchased a new stake in shares of Medtronic during the fourth quarter valued at approximately $32,000. Institutional investors and hedge funds own 82.06% of the company’s stock.
Medtronic Stock Up 1.1% Medtronic stock opened at $94.12 on Friday. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The stock has a market cap of $120.47 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 2.18 and a beta of 0.56. The company’s 50-day moving average price is $86.78 and its two-hundred day moving average price is $85.37. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52.
Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.89%. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. During the same period last year, the firm posted $1.26 earnings per share. The business’s revenue was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, analysts expect that Medtronic PLC will post 5.96 EPS for the current fiscal year. Medtronic Dividend Announcement The company also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Stockholders of record on Friday, September 25th will be given a dividend of $0.72 per share. The ex-dividend date is Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio (DPR) is 70.94%.
Trending Headlines about Medtronic Here are the key news stories impacting Medtronic this week:
Positive Sentiment: Medtronic said executives will present at the Wells Fargo Healthcare Conference on September 8 and other upcoming investor events. These appearances could provide additional updates on growth initiatives, product launches, and financial guidance. Medtronic executives to speak at upcoming investor conferences Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating, while Stifel Nicolaus, Robert W. Baird, TD Cowen, and BTIG Research maintained bullish assessments or projected meaningful price appreciation. The broad analyst support reinforces investor confidence in MDT’s outlook. Royal Bank of Canada reaffirms Outperform rating Positive Sentiment: New real-world evidence from Medtronic’s PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system. Further clinical validation could improve adoption prospects and strengthen the pain-management franchise. Medtronic’s PERSIST study builds real-world evidence Positive Sentiment: Medtronic’s latest reported quarter exceeded expectations, with earnings of $1.45 per share versus a $1.39 consensus estimate and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, providing a favorable fundamental backdrop. Neutral Sentiment: Unusually large options trading indicates elevated investor interest in MDT, but the activity does not by itself establish whether traders expect further gains or a pullback. Medtronic target of unusually large options trading Negative Sentiment: A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains. This raises the risk of profit-taking or volatility despite the positive fundamental and analyst backdrop. Healthcare stocks may be too crowded to own Insider Activity at Medtronic In other news, EVP Harry Kiil sold 4,189 shares of the company’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 0.27% of the company’s stock.
Wall Street Analysts Forecast Growth MDT has been the subject of several analyst reports. Robert W. Baird upped their target price on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research note on Wednesday. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Medtronic in a research note on Tuesday, August 18th. The Goldman Sachs Group cut their price objective on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a report on Thursday, June 4th. Rothschild & Co Redburn decreased their price objective on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research report on Friday, June 5th. Finally, BTIG Research raised their target price on Medtronic from $91.00 to $100.00 and gave the company a “buy” rating in a research note on Tuesday. Nineteen equities research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $103.92.
Check Out Our Latest Analysis on Medtronic
About Medtronic (Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Recommended Stories Five stocks we like better than Medtronic Revolution Medicines Got Its Breakthrough—What Moves It Next? Retail Earnings Just Exposed a Bigger Divide in the U.S. Consumer Economy FB Financial’s Southern Expansion and Buybacks Drive Analyst Optimism AST SpaceMobile Stock Soared 12%—This Was the Catalyst
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
Cornerstone Robotics oznámila strategické partnerství s Medtronic, které zahrnuje investici zhruba 700 mil. USD a práva na distribuci systému Sentire na vybraných trzích mimo USA. Cílem je rozšířit dostupnost robotické chirurgie po celém světě.
, /PRNewswire/ -- Cornerstone Robotics, innowacyjna firma z branży robotyki chirurgicznej założona i mająca siedzibę w Hongkongu, ogłosiła dziś strategiczne partnerstwo z Medtronic (NYSE: MDT), światowym liderem technologii medycznych. W ramach współpracy Medtronic dokona strategicznej inwestycji w Cornerstone Robotics w wysokości około 700 mln USD i uzyska prawa do dystrybucji systemu chirurgicznego Sentire™ firmy Cornerstone Robotics na wybranych rynkach poza USA, na których system jest dopuszczony do obrotu.
Wspólna wizja: zmniejszenie luki w dostępie do małoinwazyjnego leczenia chirurgicznego
W skali światowej odsetek zabiegów wykonywanych z udziałem systemów robotycznych nadal wynosi zaledwie kilka procent, dlatego możliwość udostępnienia zaawansowanego leczenia chirurgicznego większej liczbie pacjentów, lekarzy i systemów ochrony zdrowia jest tak ważna.
Rozwój tego segmentu wymaga zarówno stałych innowacji technicznych, jak i możliwości skutecznego zwiększania skali działalności rynkowej. Łącząc technologię Cornerstone Robotics z szerokim zasięgiem międzynarodowym Medtronic, obie firmy chcą udostępnić wysokiej jakości chirurgię robotyczną większej liczbie pacjentów na świecie.
Wspólny kierunek: rozwiązania technologiczne dla większej liczby pacjentów
Cornerstone Robotics zbudowała solidne podstawy rozwoju dzięki własnym pracom badawczo-rozwojowym obejmującym cały stos technologiczny oraz pionowo zintegrowanemu modelowi działania. Firma samodzielnie rozwija kluczowy sprzęt, oprogramowanie sterujące, zaawansowane algorytmy oraz własne platformy obrazowania i energii zabiegowej, dzięki czemu zachowuje istotną kontrolę nad integracją produktów, jakością i odpornością łańcucha dostaw. Przekłada się to na wyjątkową stabilność i wysoką precyzję działania systemu chirurgicznego Sentire w wymagających warunkach klinicznych.
W 2024 r. system chirurgiczny Sentire firmy Cornerstone Robotics uzyskał zatwierdzenie chińskiej National Medical Products Administration. W maju 2026 r. system Sentire otrzymał oznakowanie CE w Unii Europejskiej oraz zatwierdzenie Health Sciences Authority w Singapurze; oba obejmują małoinwazyjne zabiegi chirurgii ogólnej, ginekologicznej, torakochirurgicznej i urologicznej.
„Partnerstwo to jest ważnym krokiem w zwiększaniu dostępności chirurgii robotycznej na świecie - powiedział prof. Kwok Wai Samuel AU, założyciel i dyrektor generalny Cornerstone Robotics. - Nadal istnieje duża luka między rosnącym zapotrzebowaniem na chirurgię małoinwazyjną a dostępnością technologii chirurgii robotycznej. W Cornerstone Robotics zbudowaliśmy silne zaplecze dzięki własnym pracom badawczo-rozwojowym obejmującym cały stos technologiczny oraz integracji pionowej, co pozwala nam stale rozwijać kluczowe technologie robotyki chirurgicznej. Partnerstwo z Medtronic daje nam możliwość dalszego przyspieszenia prac i zwiększenia ich skali, aby korzyści z chirurgii robotycznej mogły trafić do większej liczby chirurgów i pacjentów na całym świecie".
„Inwestycja i umowa dystrybucyjna zwiększają możliwości Medtronic w zakresie dalszego poszerzania dostępu do chirurgii małoinwazyjnej dla pacjentów na całym świecie. Cieszymy się, że możemy zapewnić większy wybór w obszarze robotyki, a Sentire stanowi uzupełnienie naszej platformy Hugo" - powiedział Matt Anderson, Senior Vice President i President działu rozwiązań chirurgicznych w Medtronic.
Partnerstwo jest ważnym etapem dla obu firm, które wspólnie realizują misję zwiększania dostępności chirurgii robotycznej na świecie.
Doradcy
Kancelarie Kirkland & Ellis oraz Global Law Office doradzają Cornerstone Robotics w kwestiach prawnych. Morgan Stanley & Co. LLC jest wyłącznym doradcą finansowym Medtronic, a Cleary Gottlieb Steen & Hamilton LLP pełni funkcję głównego doradcy prawnego.
Cornerstone Robotics
Cornerstone Robotics, założona i mająca siedzibę w Hongkongu, jest innowacyjną firmą z branży robotyki chirurgicznej, która realizuje wizję tworzenia innowacji medycznych na rzecz zdrowszego świata. Firma usprawnia opiekę chirurgiczną dzięki zaawansowanym systemom robotycznym, które zwiększają dostępność i efektywność wysokiej jakości opieki zdrowotnej na świecie. Cornerstone Robotics ma trzy globalne ośrodki badawczo-rozwojowe i sześć centrów biznesowych na świecie oraz zakład produkcyjny w Chinach o powierzchni 30 000 m2. System chirurgiczny Sentire™, opracowany przez Cornerstone Robotics w całości we własnym zakresie, przeszedł wielospecjalistyczne badania kliniczne i został dopuszczony do obrotu w Chinach, Unii Europejskiej i Singapurze, wspierając rozwój wysokiej jakości opieki chirurgicznej na świecie.
Więcej informacji można znaleźć na stronie https://en.csrbtx.com/ oraz na profilu firmy w serwisie LinkedIn.
Medtronic
Odważne myślenie. Jeszcze odważniejsze działania. Jesteśmy Medtronic. Medtronic plc, z siedzibą w Galway w Irlandii, jest wiodącym międzynarodowym producentem technologii medycznych, który odważnie mierzy się z najtrudniejszymi problemami zdrowotnymi ludzkości, szukając i znajdując rozwiązania. Ponad 95 tys. zaangażowanych pracowników Medtronic w przeszło 150 krajach łączy wspólna misja: łagodzić ból, przywracać zdrowie i przedłużać życie. Nasze technologie i terapie stosowane są w leczeniu 70 schorzeń. Katalog Medtronic obejmuje m. in. urządzenia kardiologiczne, robotykę chirurgiczną, pompy insulinowe, narzędzia chirurgiczne, systemy monitorowania pacjentów i wiele innych. Dzięki wiedzy naszych zespołów, ich ciekawości i gotowości do pomagania potrzebującym tworzymy innowacyjne technologie, które zmieniają życie dwóch osób w każdej sekundzie, każdej godziny i każdego dnia. Nie spoczywamy na laurach: cały czas rozwijamy opiekę opartą na danych, projektujemy rozwiązania z myślą o pacjentach i personelu medycznym oraz pracujemy nad poprawą wyników leczenia na całym świecie. We wszystkim, co robimy, tworzymy rozwiązania wykraczające poza zwyczajność. Więcej informacji o Medtronic można znaleźć na stronie www.Medtronic.com oraz na profilu firmy w serwisie LinkedIn.
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 300 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.58% to 52,876.43 while the NASDAQ dipped 1.40% to 26,001.27. The S&P 500 also fell, dropping, 0.68% to 7,633.51.
Leading and Lagging Sectors
Health care shares jumped by 1.7% on Tuesday.
In trading on Tuesday, consumer discretionary stocks fell by 1.7%.
Top Headline
Medtronic PLC (NYSE:MDT) shares gained around 5% on Tuesday after the company reported better-than-expected first-quarter financial results and raised its FY27 adjusted EPS guidance.
Medtronic reported quarterly earnings of $1.45 per share which beat the analyst consensus estimate of $1.39 per share. The company reported quarterly sales of $9.756 billion which beat the analyst consensus estimate of $9.545 billion.
Trending
Also, the company announced a $700 million strategic partnership with Cornerstone Robotics to expand global access to its Sentire Surgical System in select non-U.S. markets.
Equities Trading UP
bioAffinity Technologies Inc (NASDAQ:BIAF) shares shot up 66% to $7.59 after the company announced that it is advancing the potential application of its CyPath Lung Test. Shares of Fly-E Group Inc (NASDAQ:FLYE) got a boost, surging 45% to $1.99. Wetour Robotics Ltd (NASDAQ:WETO) shares were also up, gaining 50% to $8.21 after the company announced it released a development demonstration of Orchestra combining surface electromyography with first-person vision to capture richer human-hand data for robot learning. Equities Trading DOWN
Alumis Inc (NASDAQ:ALMS) shares dropped 50% to $10.86 after the company disclosed topline results from Envudeucitinib Phase 2b trial in Systemic Lupus Erythematosus (SLE). Shares of KALA BIO Inc (NASDAQ:KALA) were down 19% to $0.54. Kala Bio and Virotek announced a Letter of Intent to establish an exclusive U.S. distribution partnership for ophthalmology genetic testing program. Nocera Inc (NASDAQ:NCRA) was down, falling 21% to $2.23. Commodities
In commodity news, oil traded up 2.9% to $88.20 while gold traded down 2.3% at $4,376.60.
Silver traded down 3.2% to $64.875 on Tuesday, while copper fell 1.6% to $6.5795.
Euro zone
European shares were lower today. The eurozone’s STOXX 600 slipped 0.5%, while Spain’s IBEX 35 Index fell 0.7%, London’s FTSE 100 fell 0.6%, Germany’s DAX dipped 0.9%, while France’s CAC 40 fell 0.3%.
Asia Pacific Markets
Asian markets closed lower on Tuesday, with Japan’s Nikkei 225 falling 0.15%, Hong Kong’s Hang Seng index declining 0.93%, China’s Shanghai Composite declining 0.16% and India’s BSE Sensex falling 0.02%.
Economics
The US Logistics Managers’ Index declined for a second straight month to a reading of 66.6 in August from 68.9 in the previous month.
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Medtronic oznámil strategickou investici do Pi-Cardia až za 80 milionů USD a získá opci na převzetí firmy za odhadovaných až 210 milionů USD. Zároveň má být od roku 2027 výhradním globálním distributorem zařízení ShortCut pro komplexní TAVR.
, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and Pi-Cardia Ltd., a pioneer in leaflet modification technologies for structural heart disease, today announced a strategic investment by Medtronic in Pi-Cardia Ltd. With a focus on addressing the evolving needs of increasingly complex transcatheter aortic valve replacement (TAVR) patients and procedures, Medtronic secures an option for strengthening its structural heart portfolio through this strategic investment, supporting the next generation of innovation.
Pi-Cardia ShortCut™ Device Pi-Cardia's ShortCut™ device is the first FDA-cleared leaflet modification technology designed to enable valve-in-valve TAVR procedures in patients at risk of coronary obstruction. The device provides physicians with a safe, easy-to-learn, reproducible approach to leaflet modification that can help preserve coronary access and enable future transcatheter valve procedures. In FDA-reviewed clinical studies, ShortCut™ demonstrated successful leaflet splitting in all pivotal trial patients and a favorable safety profile.
"As structural heart care evolves, we're investing in technologies that help physicians address today's challenges while preparing for tomorrow's opportunities," said Jorie Soskin, vice president and general manager of the Structural Heart business within Medtronic's Cardiovascular portfolio. "Our investment in Pi-Cardia reflects our commitment to building a portfolio of technologies that will shape the future of TAVR, particularly for patients with complex anatomy. We believe leaflet modification technologies like ShortCut have the potential to become an important component of structural heart care and the future of TAVR as transcatheter therapies continue to advance."
Under the agreement, Medtronic will make strategic investments of up to $80 million into Pi-Cardia and is expected to become the exclusive global commercial distributor of the ShortCut device in 2027. Medtronic will leverage its worldwide Structural Heart organization to expand physician access across the United States, Europe, Japan and other international markets. The agreement also includes an option for Medtronic to acquire Pi-Cardia upon achievement of predefined milestones for an estimated upfront acquisition price of up to $210 million, subject to customary adjustments, plus additional potential earn-out payments post-acquisition that could meaningfully increase the total consideration. The transactions are subject to regulatory approval and customary closing conditions.
"Our mission has been to make leaflet modification a standard part of complex TAVR," said Erez Golan, Chief Executive Officer of Pi-Cardia. "Medtronic is the right partner to help us achieve this vision given their global reach and commitment to bringing innovative tools to physicians and patients worldwide. We are confident this collaboration will accelerate adoption of ShortCut while continuing to advance the future of leaflet modification."
The strategic investment secures an option for Medtronic to strengthen its structural heart portfolio by adding a first-of-its-kind technology that addresses a significant challenge in valve-in-valve TAVR while complementing the company's leadership in transcatheter valve therapies. It also reflects Medtronic's commitment to partnering and investing early in innovations that can improve patient outcomes, expand future treatment options, and support long-term growth.
Pi-Cardia was founded by Erez Golan and Eyal Kolka, and is backed by experienced medtech investors including Sofinnova Partners, Sprig Equity, and Jacques Séguin, whose commitment has helped advance the company's vision of developing transformative leaflet modification technologies.
About Pi-Cardia
Pi-Cardia Ltd. is a privately held medical device company dedicated to developing innovative structural heart technologies that address unmet clinical needs. Its proprietary leaflet modification platform is designed to improve procedural outcomes and expand treatment options for patients undergoing transcatheter valve interventions.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission, to alleviate pain, restore health, and extend life, unites a global team of employees dedicated to transforming healthcare and improving lives around the world.
Contacts:
Kimberly Powell
Public Relations
+1-202-498-2601
Ingrid Goldberg
Investor Relations
+1-763-505-2696
Medtronic v 1Q fiskálního roku 2027 překonal odhady tržbami 9,76 mld. USD i očištěným EPS 1,45 USD a zvýšil celoroční výhled organického růstu tržeb i zisku na akcii. Akcie v předburzovní fázi přidávají 5,01 %.
Výrobce zdravotnických zařízení Medtronic zveřejnil výsledky za první kvartál fiskálního roku 2027, který skončil 31. července 2026. Tržby i očištěný zisk na akcii překonaly odhady trhu a společnost zároveň zvýšila celoroční výhled organického růstu tržeb i zisku na akcii.
Výsledky společnosti Medtronic (MDT) za 1Q FY 2027 1Q FY 2027 Konsensus 1Q FY2027 1Q FY 2026 Tržby (mld. USD) 9,76 9,54 8,54 Čistý zisk (mld. USD) 1,86 -- 1,63 Očištěný zisk na akcii (EPS, USD/akcie) 1,45 1,39 1,26 Výsledky za 1Q Tržby v prvním kvartále vzrostly meziročně o 13,7 % na 9,76 mld. USD, na organické bázi rovněž o 13,7 %. Do čísel se promítl navíc jeden fiskální týden, jehož přínos k organickému růstu firma odhaduje přibližně na 570 mil. USD.
Očištěná hrubá marže zaznamenala meziroční růst o 10 bazických bodů na 65,2 %. Trh projektoval 64,8 %.
Tržby Medtronicu v 1Q FY 2027 dle segmentů
(v mld. USD) Segment Tržby Konsenzus Meziroční změna Kardiovaskulární 3,93 3,78 +19,5 % Neurověda
2,68 2,66 +10,3 % Lékařsko-chirurgický
2,28 2,25 +10,0 % Diabetologie 0,84 0,82 +16,9 % Tahounem zůstal kardiovaskulární segment, v němž divize Cardiac Ablation Solutions vzrostla o 88 %, v USA dokonce o 139 %, a meziročně získala 9procentních bodů amerického tržního podílu. Cardiac Rhythm Management přidal 15 % a divize Cranial & Spinal Technologies 13 %. Z hlediska regionů rostly tržby v USA organicky o 15,8 % na 4,91 mld. USD, mimo USA o 11,6 % na 4,85 mld. USD.
Očištěná provozní marže dosáhla 23,7 % oproti 23,6 % před rokem, přičemž odhad trhu činil 23,8 %.
V průběhu kvartálu Medtronic dokončil akvizice společností Scientia Vascular a SPR Therapeutics. Zároveň oznámil strategickou investici a distribuční dohodu se společností Cornerstone Robotics týkající se systému Sentire na vybraných trzích mimo USA.
Výhled Společnost zvýšila celoroční výhled a pro fiskální rok 2027 nyní očekává:
Organický růst tržeb o 7,25 až 7,75 %, tedy o 50 bazických bodů více než dosavadních 6,75 až 7,25 %. Očištěný zisk na akcii v rozmezí 5,94 až 6,00 USD oproti předchozím 5,90 až 6,00 USD. Odhad Wall Street byl na úrovni 5,96 USD. Výhled zahrnuje vliv měnových kurzů na zisk na akcii v rozmezí neutrálního dopadu až 1% přínosu, u tržeb naopak negativní dopad 50 až 150 mil. USD.
Výhled také nadále zahrnuje diabetologický segment po celý fiskální rok 2027. Oddělení tohoto byznysu chce společnost dokončit ještě před koncem fiskálního roku a po jeho realizaci výhled aktualizuje.
Komentář vedení „Fiskální rok 2027 jsme zahájili silně. Důvěru nám nedodává pouze samotná síla tohoto kvartálu, ale především šíře výkonnosti napříč našimi obchodními jednotkami a rostoucí příspěvek novějších růstových platforem,“ uvedl generální ředitel Geoff Martha. „Naše realizační schopnost spolu s inovačním motorem nám umožňuje pomáhat většímu počtu pacientů a dosahovat udržitelného růstu. Síla našeho portfolia a připravovaných inovací nám dodává jistotu ohledně příležitostí, které máme před sebou.“
„Nadále cíleně investujeme do inovací, rozvoje portfolia a obchodní realizace, což podpoří udržitelnou dlouhodobou tvorbu hodnoty,“ uvedl finanční ředitel Thierry Piéton. „Kombinace silné provozní výkonnosti a disciplinovaného finančního řízení dostala tržby i očištěný zisk na akcii nad očekávání, což nám umožnilo zvýšit výhled pro fiskální rok 2027.“
Akcie Medtronic Akcie Medtronic (MDT) v předburzovní fázi obchodování posilují o 5,01 % na 95,19 USD.
Čtyři zdravotnické akcie — Johnson & Johnson, Abbott, Medtronic a Becton, Dickinson — zvyšovaly čtvrtletní dividendy i během recesí v letech 2008–2009 a při covidovém šoku. Jde o firmy s odolnou tvorbou hotovosti a dlouhými sériemi růstu výplat.
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made it happen and whether their income streaks can…
Two recessions inside two decades tested every corner of the market, and a small club of healthcare names paid you more every year through both. The 2008 to 2009 downturn and the 2020 COVID shock hit consumer spending, elective procedures, and hospital budgets, yet the four healthcare stocks below kept raising quarterly dividends the entire way. The shared hook is durability. Abbott CEO Robert Ford recently told investors that “diagnostic test results inform approximately 70% of all healthcare decisions, making testing volumes a reliable barometer of overall healthcare activity and demand,” and that demand held up in both slowdowns. Here is what the income math looks like today across four blue-chip healthcare dividend growers.
Johnson & Johnson: 64 Years of Raises and a $21 Billion FCF Machine Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) trades at $266.60 and carries a dividend yield of 1.97%, with an annualized forward payout of $5.36 per share after the April increase from $1.30 to $1.34 quarterly.
J&J ended Q2 2026 with roughly $21 billion in cash and marketable securities, guided full-year free cash flow “approaching $21 billion,” and posted year-to-date FCF of about $8.7 billion. Trailing EPS of $8.68 comfortably covers the $5.24 trailing dividend. The dividend history file shows uninterrupted quarterly payments stretching back to 1999, and management flagged 64 consecutive years of dividend increases at its Q1 earnings.
The bull case for income holders simply comes down to diversification. CFO Joe Wolk described a “broad, durable portfolio that has 28 platforms, each generating more than $1 billion in annual revenue,” and reiterated that J&J “remain[s] committed to returning capital directly to shareholders, primarily through our dividend.” Oncology is doing the heavy lifting, with Darzalex up 17.6%, Carvykti up 47.7%, and Tremfya up 71% in Q2. Shares are up 31.6% year to date.
The most visible risk with this stock seems to be Stelara as sales fell 55.7% in Q2 on biosimilar competition, a headwind that will linger into 2027.
Abbott Laboratories: A Dividend Aristocrat With a 54-Year Streak Abbott Laboratories (NYSE:ABT) trades at $110.10 after a 8.57% pullback year to date, which has lifted the yield to 2.22%. The quarterly payout rose from $0.59 to $0.63 this year, and the annualized forward is $2.52.
Abbott is a bona fide S&P 500 Dividend Aristocrat with 54 consecutive years of raises and paid its 410th consecutive quarterly dividend in August. Trailing EPS of $3.12 covers the $2.48 trailing dividend, and Q2 shareholder returns totaled $2.1 billion via dividends and buybacks. The company operates with a low 0.581 beta, useful in a defensive sleeve.
The bull case for this stock is portfolio breadth. Q2 comparable sales grew 4.8%, adjusted EPS came in at $1.31, and full-year adjusted EPS guidance was raised to $5.45 to $5.60. Continuous glucose monitoring sales cleared $2 billion in the quarter growing 9.5%, and cancer diagnostics grew 13%. Ford summed it up: “Demand for high acuity, life-saving products is very inelastic.”
The risk for Abbott is its nutrition segment which slipped 3.1%, not to mention, CGM competition from Dexcom is continuing to intensify.
Medtronic: Highest Yield in the Group, Backed by $5.4 Billion in FCF Medtronic (NYSE:MDT) is the yield leader of this bundle at 3.16%, with shares at $90.83. The board bumped the quarterly payout from $0.71 to $0.72 in June, taking the annualized forward to $2.88. Management has raised the dividend for 49 consecutive years, one shy of the 50-year Dividend King club (we ranked ten current Kings by valuation in a free report here).
Fiscal 2026 free cash flow was $5.4 billion, “the strongest it has been since 2022”, and Medtronic ended the year with $9.2 billion in cash and investments. Trailing EPS of $3.79 covers the $2.84 trailing dividend, and the forward P/E of 15 is well below Abbott’s 20 and J&J’s 23.
Q4 revenue grew 9.9%, appeasing the bulls and capping the company’s “strongest top-line performance in 10 years.” Cardiac ablation delivered 78% worldwide growth, with pulsed field ablation (PFA) up 145% globally. FY27 guidance calls for organic revenue growth of 6.75% to 7.25% and adjusted EPS of $5.90 to $6.00.
On the other hand, Medtronic absorbed roughly $185 million of tariff pressure in FY26, and the pending Diabetes business separation adds execution complexity.
Becton, Dickinson: Post-Spin Cash Machine Buyers Are Rediscovering Becton, Dickinson (NYSE:BDX) rounds out this bundle at $188.67, up 25.88% year to date, and yielding 2.23%. The quarterly dividend stepped up to $1.05 this year, with an annualized forward of $4.20. Dividend records show continuous quarterly payments and steady annual increases from $0.37 in 2010 to $1.05 in 2026, a track record that ran uninterrupted through both recessions in the file.
Year-to-date FCF was $1.7 billion, an increase of 45% versus the prior year. CFO Vitor Roque said “Year to date, we returned $3.1 billion to shareholders, including approximately $2.3 billion in share repurchases, and $0.9 billion in dividends,” while CEO Tom Polen reiterated the target of “90% free cash flow conversion… over time.” Trailing EPS of $5.82 covers the $4.19 trailing dividend, and the forward P/E of 14 is the cheapest in this group.
The bull case for Becton Dickinson is that this is the first full quarter as the more focused “new BD” after the February 2026 Biosciences and Diagnostics spinoff. Q3 revenue was $5 billion, up 4.4%, adjusted EPS was $3.23, up 4.9%, and full-year adjusted EPS guidance was raised to $12.62 to $12.72. Optionality on GLP-1 injection pens (roughly 100 agreements across novel and biosimilar programs) is a genuine growth kicker.
The risk still remains its post-spin transition. FY27 revenue is guided to low single-digit growth as the alarmist remediation headwind runs off, and net leverage sits at 2.9 times versus a 2.5 times long-term target.
Bottom Line for Income Investors These four names offer durability over headline yield. J&J, Abbott, Medtronic, and BD paid rising dividends straight through the Global Financial Crisis and the COVID shock because their cash generation runs on inelastic demand: drugs, diagnostics, devices, and the plumbing hospitals cannot skip. Medtronic delivers the fattest yield today, BD offers the lowest multiple, Abbott brings Aristocrat pedigree, and J&J anchors the group with 28 billion-dollar platforms and a 64-year raise streak. For a defensive income sleeve built to survive the next downturn, this is the healthcare shortlist.
Contact [email protected] for any questions or corrections.
Medtronic čeká na výsledky za 1. fiskální čtvrtletí, přičemž trh počítá s EPS 1,39 USD a tržbami 9,47 mld. USD. Největšími tahouny mají být Cardiovascular a Diabetes.
Key Takeaways Medtronic expects Q1 growth across Cardiovascular, Neuroscience, MedSurg and Diabetes.MDT's Cardiovascular growth may be led by PFA momentum and strength in Cardiac Rhythm Management.MDT's MiniMed launches and sensor integrations are expected to boost Diabetes revenues. Medtronic plc (MDT - Free Report) is slated to report its first-quarter fiscal 2027 results on Sept. 1, before the opening bell.
The Zacks Consensus Estimate for the company’s first-quarter earnings per share (EPS) suggests 10.3% year-over-year growth to $1.39. The estimate has remained constant in the past 60 days. The consensus mark for first-quarter revenues currently stands at $9.47 billion, implying a 10.4% increase over the prior-year period.
Image Source: Zacks Investment Research
Medtronic has a solid earnings surprise history, beating estimates in each of the past four quarters, with an average surprise of 2.3%.
Image Source: Zacks Investment Research
Q1 Earnings Whispers for MDTPer our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below.
Earnings ESP: Medtronic has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here.
Factors Likely to Have Shaped MDT’s Q1 PerformanceCardiovascularThe segment is likely to have witnessed a solid performance across both U.S. and international markets. Within this, Cardiac Ablation Solutions (“CAS”) is expected to have remained the key growth driver, supported by momentum in the pulsed field ablation portfolio, which grew 145% in the previous quarter. The launch of the Sphere-9 catheter in Japan may have also strengthened Medtronic’s position in the region.
The company has also begun the global rollout of Prism-2, its next-generation mapping software, which offers improved navigation through hybrid impedance and magnetic mapping. In June 2026, Medtronic announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies, which may have provided an additional boost to revenues.
Cardiac Rhythm Management may also have contributed, driven by Micra leadless pacemakers, Aurora implantable cardioverter defibrillator (EV-ICD) system and the SelectSecure 3830 lead.
In Structural Heart, revenues are expected to have benefited from continued international strength as well as stabilizing U.S. procedure volumes. Growth in the Symplicity Spyral renal denervation system, guide catheters and balloons, as well as Endovenous growth in Peripheral Vascular Health, may have boosted Coronary & Peripheral Vascular sales.
The Zacks Consensus Estimate implies Cardiovascular revenues will increase 15.2% year over year.
NeuroscienceMedtronic continues to invest across its Neuroscience portfolio to advance pipeline innovation and support long-term growth. Within this, Cranial and Spinal Technologies results in the fiscal first quarter may benefit from the continued adoption of the AiBLE ecosystem, with Core Spine and Neurosurgery also likely contributing to growth. The commercial rollout of the Stealth AXiS surgical system may have further advanced. In June, Medtronic received the CE mark for the ear, nose and throat indications, expanding the platform’s reach.
Neuromodulation performance is expected to have been led by the Inceptiv closed-loop spinal cord stimulator, the Percept RC neurostimulator with BrainSense technology, and Interventional products.
Medtronic completed two acquisitions within this business. The Scientia Vascular acquisition in June adds a portfolio of guidewires and catheters to its existing neurovascular product lineup, while the July acquisition of SPR Therapeutics, Inc. (SPR) expands its ability to serve patients across the pain care continuum.
The Zacks Consensus Estimate expects Neuroscience revenues to grow 10.7% year over year.
Medical Surgical (MedSurg)In the fiscal first quarter, MedSurg performance is expected to have been driven by solid growth in Advanced Energy and Wound Management, alongside higher contribution from the Hugo robotic-assisted surgery system. However, similar to recent trends, continued pressure on U.S. bariatric surgery procedure volumes may have partially offset this growth.
Endoscopy is likely to have been a growth driver, with sales benefiting from strong adoption of Endoflip in the United States and Western Europe, as well as from U.S. market share gains of the Nexpowder hemostasis system. Acute Care and Monitoring may have gained from strength in Nellcor pulse oximetry, respiratory and airways and in perioperative.
The Zacks Consensus Estimate for MedSurg’s revenues suggests a 7.6% year-over-year increase.
DiabetesMiniMed, Medtronic’s diabetes business, completed an initial public offering in March, with approximately 10% of its ownership sold and its shares beginning to trade on the Nasdaq Global Select Market. Medtronic continues to hold approximately 90% ownership in MiniMed.
In the first quarter of fiscal 2027, the business is likely to have witnessed robust international contributions from the continued adoption of the MiniMed 780G Automated Insulin Delivery (AID) system, including the Simplera Sync and Guardian 4 continuous glucose monitoring sensors and Extended Infusion Sets. U.S. momentum may also have continued following the late-2025 launches of the Simplera Sync and Abbott’s Instinct sensors.
The quarter also saw several key developments. MiniMed announced the commercial availability of MiniMed Flex, its smallest app-controlled insulin pump powered by the advanced SmartGuard algorithm. The system is FDA cleared for people with type 1 diabetes aged 7 years and older, as well as adults aged 18 years and older with insulin-requiring type 2 diabetes and is paired with the Simplera Sync sensor. MiniMed Flex is also now available to Medicare and Medicare Advantage beneficiaries.
MiniMed launched the MiniMed 780G system integrated with Abbott’s Instinct sensor and the MiniMed Go system with the Instinct Go sensor in Europe. Together, these developments are expected to have strongly boosted overall revenues in the quarter.
The Zacks Consensus Estimate suggests Diabetes revenues will grow 15.1% year over year.
MDT Stock Price PerformanceOver the past three months, Medtronic shares have outperformed the industry and the broader Medical sector.
Image Source: Zacks Investment Research
The stock has also fared better than major peers like Boston Scientific (BSX - Free Report) , whose shares fell 2%, while Edward Lifesciences (EW - Free Report) gained 4.8%. Boston Scientific’s second-quarter 2026 revenues and EPS surpassed the Zacks Consensus Estimate by 1.1% and 3.6%, respectively. However, the company lowered its 2026 sales and earnings outlook after slower WATCHMAN demand, U.S. electrophysiology share losses and limited operating leverage weakened near-term visibility. Meanwhile, Edwards’ second-quarter revenues and EPS topped the consensus mark by 2.4% and 6.8%, respectively.
MDT’s ValuationMedtronic trades at a forward five-year Price/Earnings (P/E) of 14.98X, lower than its median of 15.73X and the industry average of 17.74X.
Image Source: Zacks Investment Research
EndnoteMedtronic’s upcoming fiscal first-quarter results are expected to reflect ongoing momentum in CAS, as well as strength in businesses such as Cardiac Rhythm Management and Cranial and Spinal Technologies. At the same time, the company is also advancing its M&A and venture initiatives, targeting higher-growth segments to accelerate innovation.
While current indicators do not point to a strong earnings beat, the company has a consistent earnings surprise history, which is encouraging. Medtronic’s recent stock performance has been impressive, outpacing the key benchmarks and peers. Existing MDT shareholders should consider holding their positions, supported by the company’s attractive valuation.
Intuitive Surgical ve 2. čtvrtletí 2025 zvýšila tržby o 19 % a počet výkonů o 16 %, přičemž opakující se příjmy tvoří 85 % prodejů. Firma má po celém světě téměř 13 000 systémů da Vinci a Ion.
Key Takeaways Intuitive Surgical's Q2 2026 revenue rose 19%, while procedures increased 16% on strong platform adoption.ISRG gets 85% of sales from recurring revenue, supported by nearly 13,000 da Vinci and Ion systems globally.MDT trades at a lower forward P/E and is expanding Hugo while investing across digital surgery and MedTech. Robotic surgery remains one of MedTech's fastest-growing battlegrounds, but not all players are competing from the same starting line. Intuitive Surgical (ISRG - Free Report) continues to widen its lead as da Vinci procedure growth, system placements and recurring revenue reinforce the strength of its installed-base model. Meanwhile, Medtronic (MDT - Free Report) is steadily building momentum with Hugo, pairing its robotics push with broader investments across digital surgery and surgical technologies.
The latest earnings highlight two distinct growth stories. Intuitive Surgical posted another quarter of double-digit revenue and procedure growth, supported by strong adoption of da Vinci 5, the single-port platform and the Ion lung biopsy system. Medtronic, on the other hand, delivered its strongest top-line performance in a decade while expanding Hugo placements, increasing system utilization and advancing U.S. regulatory milestones that could broaden the platform's reach.
The contrast raises an important question for investors: Is Intuitive Surgical's established robotics ecosystem still the superior long-term bet, or can Medtronic's diversified portfolio and expanding surgical platform narrow the gap over time?
Let's get into more detail to find out.
Price PerformanceSo far this year, Intuitive Surgical has plunged 34.4%, significantly underperforming Medtronic's 5.1% decline. The contrast is even sharper against the broader benchmarks, with the Medical sector gaining 6.2% and the S&P 500 advancing 11.4% over the same period.
ISRG's YTD Price Performance
Image Source: Zacks Investment Research
ISRG vs. MDT: Four Key Factors That Separate These Robotics PlayersCommercial Momentum
Intuitive Surgical continues to set the pace in surgical robotics, with second-quarter 2026 revenues rising 19% and total procedures increasing 16%. The company's ecosystem remains the key differentiator as recurring revenue now accounts for 85% of sales, while the installed base approaches 13,000 da Vinci and Ion systems globally. Strong adoption of da Vinci 5, SP and Ion platforms reinforces a flywheel where higher procedure volumes fuel recurring instrument and service revenue.
Medtronic is generating healthy growth, but its robotics business remains at an earlier stage. Fiscal fourth-quarter revenues climbed 9.9%, marking the company's strongest annual top-line performance in a decade, while Hugo delivered procedure growth running two to three times the market alongside improving utilization. Unlike Intuitive Surgical, however, robotics remains one piece of Medtronic's much broader MedTech portfolio rather than its primary growth engine.
Product Innovation and Platform Expansion
Innovation remains central to Intuitive Surgical's leadership strategy. During the second quarter, the company expanded da Vinci 5 with the first wave of more than 100 planned software updates, advanced SP through broader stapler adoption, continued scaling Ion internationally and submitted a next-generation flexible robotic endoscope for FDA review. Management continues investing heavily across AI, imaging and robotics to widen the platform's long-term advantage.
Medtronic is aggressively expanding the Hugo ecosystem beyond the robot itself. The company launched Hugo for U.S. urology, submitted additional FDA clearances covering general surgery, gynecology and robotic vessel sealing, while growing its Touch Surgery digital ecosystem by more than 30% sequentially. Management is pairing Hugo with digital surgery, imaging and analytics capabilities to create a broader surgical platform over time.
Growth Runway and Market Expansion
Intuitive Surgical continues finding new avenues for expansion even as it dominates robotic surgery. International da Vinci procedures grew 20%, SP procedures surged 61% and Ion procedures jumped 36%, while markets like India, Japan and Europe provided fresh momentum despite ongoing pressure in China. The company is also pushing into newer areas such as cardiac procedures, nipple-sparing mastectomies and high-volume benign surgeries to extend its addressable market.
Medtronic's opportunity extends well beyond Hugo. The company is simultaneously expanding Affera in pulsed-field ablation, accelerating Symplicity for hypertension, growing Stealth AXiS in neurosurgery and pursuing tuck-in acquisitions across pain management and neurovascular care. This diversified approach gives Medtronic multiple growth drivers, although its surgical robotics opportunity is still in the early stages of commercialization.
Profitability and Investment Strategy
Intuitive Surgical continues balancing strong profitability with elevated innovation spending. The company delivered a 42% non-GAAP operating margin while increasing R&D faster than SG&A, reflecting management's willingness to reinvest from a position of financial strength. Healthy cash generation and a sizable cash balance provide flexibility to fund future product development without sacrificing operational discipline.
Medtronic is pursuing a different playbook by accepting near-term cost pressure to accelerate long-term growth. The company increased investments across R&D, commercial expansion, acquisitions and venture funding while absorbing tariff headwinds, yet still beat earnings expectations and guided for 6.75%-7.25% organic revenue growth in fiscal 2027. Management believes this investment cycle will strengthen leadership across several high-growth MedTech categories over time.
Estimates PictureFor 2026, the Zacks Consensus Estimate for ISRG’s bottom line is pegged at $10.74 per share, implying a 20.3% improvement over the 2025 reported figure.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MDT’S fiscal 2027 bottom line is pegged at $5.94 per share, implying 7.4% growth over the 2025 reported figure.
Image Source: Zacks Investment Research
Valuation ComparisonISRG currently trades at a forward 12-month P/E multiple of 32.26, above the Medical Instrument industry's 26.78, indicating the market continues to assign a premium to its long-term growth profile.
Image Source: Zacks Investment Research
MDT currently trades at a forward 12-month P/E multiple of 14.98, below the Medical Products industry's 17.74, suggesting a relatively attractive valuation compared with its peer group.
Image Source: Zacks Investment Research
Final Take: ISRG or MDT?Intuitive Surgical appears to have the edge following the latest earnings, backed by stronger procedure growth, accelerating da Vinci 5 adoption and a high-margin recurring revenue model that continues to reinforce its leadership in robotic surgery. Medtronic, meanwhile, delivered its strongest top-line performance in a decade while making steady progress with Hugo, but its robotics business remains earlier in its commercialization journey.
From a Zacks perspective, both stocks carry a Zacks Rank #3 (Hold), suggesting investors may want to remain selective. ISRG stands out for its stronger Growth Score of B, while MDT offers the more attractive valuation profile with a Value and overall VGM Score of B. Investors seeking faster growth may lean toward ISRG, whereas those prioritizing value and diversification may find MDT the more balanced choice.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Medtronic uvedl, že průměrný týdenní počet výkonů Symplicity Spyral po rozhodnutí Medicare zdvojnásobil a roční tempo už dosahuje 100 milionů USD. Zároveň ale ve fiskálním roce 2027 čeká dopad cel do COGS asi 250 milionů USD a možný tlak z kurzů.
Key Takeaways Medtronic's Cardiovascular business grew 9.3% organically in fiscal 2026, led by strong rhythm growth.MDT's Hypertension momentum builds as Symplicity Spyral gains access and procedures double after the NCD.Medtronic faces tariff costs and currency risks, with fiscal 2027 guidance signalling a revenue drag. Medtronic plc (MDT - Free Report) is well-poised for growth in the upcoming quarters due to strong momentum in its Cardiovascular businesses, both in the United States and internationally. In Neuroscience, the company is investing across the portfolio to advance pipeline innovation and long-term growth. Medtronic’s Hypertension business could benefit from a large unmet need as renal denervation moves into broader use. Yet, macroeconomic pressures and adverse foreign exchange impacts may weigh on the company’s results.
Over the past year, this Zacks Rank #3 (Hold) stock has gained 0.1% against the industry’s 23.1% decline and the S&P 500 composite’s 20.2% rise.
The renowned medical device company has a market capitalization of $116.67 billion. Medtronic has an earnings yield of 6.5% compared with the industry’s yield of 2.6%. MDT’s earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 2.3%.
Let’s delve deeper.
Tailwinds for MDTMarket Share Gain Within Cardiovascular to Continue: Medtronic is expanding its global foothold within the Cardiovascular business. Fiscal 2026 Cardiovascular revenues grew 9.3% organically, while fourth-quarter revenues rose 10.1% organically, led by 18.2% growth in Cardiac Rhythm & Heart Failure. Cardiac Ablation Solutions delivered 78% growth, including 124% growth in the United States, and gained 8 U.S. share points.
Cardiac Rhythm Management grew in the mid-single digits, supported by Micra, the SelectSecure 3830 lead, Aurora EV-ICD and OmniaSecure. Peripheral Vascular Health also benefits from the full market release of Liberant mechanical thrombectomy and Neuroguard IEP carotid stenting. These platforms support continued share capture across several cardiovascular categories, while fiscal 2027 commentary calls for Cardiovascular performance broadly in line with fiscal 2026.
Image Source: Zacks Investment Research
Neuroscience Portfolio Shows Growth Prospects: Medtronic’s Neuroscience portfolio remains broad, with growth opportunities across Cranial & Spinal Technologies, Specialty Therapies and Neuromodulation. Fiscal 2026 Neuroscience revenues rose 3.1% organically, and fourth-quarter growth was 3% organically, led by 6% growth in international markets. Within CST, Core Spine grew 6% in the fourth quarter, supported by ModuleX expansion and distributor conversions.
Stealth AXiS secured FDA clearance for spine, cranial and ENT indications and CE Mark for spine and cranial indications, which broadens the platform’s contribution to AiBLE. Specialty Therapies grew 3.4% organically in the fourth quarter, while Neurovascular rose 6% as hemorrhagic products advanced 11% with Neuroguard and Artisse adoption. In Pelvic Health, Altaviva is gaining traction, with active implanters up threefold sequentially and patients treated up 2.5 times. In Neuromodulation, SPR Therapeutics and ViaVerte expand Medtronic’s reach into chronic pain therapies and BVNA.
Hypertension, A New Focus Area: Medtronic’s Hypertension business is entering a broader commercial ramp-up through the Symplicity Spyral renal denervation procedure. The final Medicare National Coverage Determination enabled broader access, and procedure momentum improved after reimbursement clarity. Management noted that average weekly procedures doubled after the NCD, and Symplicity is now annualizing at $100 million.
The company estimates roughly 18 million people in the United States live with uncontrolled hypertension despite multiple medications. Long-term data in more than 2,000 patients showed sustained mean systolic BP reductions of 13.3 millimeters of mercury in ambulatory settings and 18.1 millimeters of mercury in office settings in three years. This evidence, combined with expanding reimbursement and patient demand, supports management’s view that renal denervation can become a multi-billion-dollar opportunity over time.
Downsides for MDTMacroeconomic Issues Hamper Market Growth: Medtronic’s operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. Tariffs impacted the business by 80 basis points (bps) in the fourth quarter of fiscal 2026 after a 110 bps impact in the third quarter. For fiscal 2027, management expects tariff impact on the cost of goods sold (COGS) of approximately $250 million, up $65 million year over year, with no government refund assumed.
Exposure to Currency Movement: Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag.
MDT Stock Estimate TrendThe Zacks Consensus Estimate for Medtronic’s fiscal 2027 earnings per share (EPS) has remained constant at $5.94 in the past 30 days.
The consensus estimate for the company’s fiscal 2027 revenues is pegged at $38.64 billion, implying a 6.3% increase from the year-ago reported number.
Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and Teleflex (TFX - Free Report) .
Globus Medical has an earnings yield of 5.8% compared to the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED shares have rallied 35.1% against the industry’s 3.5% decline over the past year.
GMED sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Veracyte, sporting a Zacks Rank #1, has an earnings yield of 4.6% against the industry’s negative 1.7% yield. Shares of the company have risen 47.8% against the industry’s 3.5% plunge. VCYT’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 41.8%.
Teleflex, carrying a Zacks Rank #2 (Buy), has an estimated long-term earnings growth rate of 20.7% compared with the industry’s 12.8% growth. Its earnings beat estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 3.2%. TFX shares have rallied 9.9% against the industry’s 3.5% fall over the past year.
, /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 20, 2026, approved the company's cash dividend for the second quarter of fiscal year 2027 of $0.72 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in June 2026. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 49 consecutive years. The dividend is payable on October 16, 2026, to shareholders of record at the close of business on September 25, 2026.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Contacts:
Justin Paquette
Public Relations
+1-612-271-7935
Ingrid Goldberg
Investor Relations
+1-763-505-2696
Fox Run Management L.L.C. lifted its stake in Medtronic PLC (NYSE:MDT – Free Report) by 364.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,397 shares of the medical technology company’s stock after acquiring an additional 18,364 shares during the period. Fox Run Management L.L.C.’s holdings in Medtronic were worth $1,830,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Medtronic by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 128,961,343 shares of the medical technology company’s stock valued at $12,388,027,000 after purchasing an additional 1,888,381 shares during the last quarter. State Street Corp lifted its position in shares of Medtronic by 2.0% during the fourth quarter. State Street Corp now owns 61,660,158 shares of the medical technology company’s stock valued at $5,966,780,000 after buying an additional 1,199,621 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Medtronic by 2.7% during the fourth quarter. JPMorgan Chase & Co. now owns 53,616,694 shares of the medical technology company’s stock valued at $5,150,420,000 after buying an additional 1,419,730 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of Medtronic by 12.6% in the 4th quarter. Capital Research Global Investors now owns 34,573,163 shares of the medical technology company’s stock valued at $3,321,101,000 after buying an additional 3,880,174 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of Medtronic by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 27,879,481 shares of the medical technology company’s stock valued at $2,665,832,000 after buying an additional 231,919 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.
Medtronic News Roundup Here are the key news stories impacting Medtronic this week:
Positive Sentiment: Medtronic outperformed the broader market in the latest session, closing higher as investors focused on the company’s defensive medical-device exposure. Medtronic Advances While Market Declines Positive Sentiment: Seventeen analysts have issued targets over the past six months, with a median target of $101, implying additional upside from recent levels. Targets range widely, however, from $83 to $119. Medtronic Analyst Targets and Trading Data Neutral Sentiment: Value-focused coverage is comparing MDT with Agilent Technologies, indicating that investors are evaluating Medtronic’s valuation against peers rather than responding to a major new company-specific catalyst. MDT Versus Agilent for Value Investors Neutral Sentiment: Institutional positioning was mixed in the latest reported quarter: 998 investors increased holdings while 1,327 reduced positions, including sizable additions by JPMorgan and reductions by Capital Research and UBS. Medtronic Institutional Activity Negative Sentiment: Quiver estimated CEO Geoff Martha’s 2026 compensation at $22.9 million, up 7.4% year over year. It also reported eight open-market insider sales and no purchases over the past six months, which may raise governance and confidence concerns. Medtronic CEO Compensation and Insider Sales Negative Sentiment: BTIG reaffirmed a “buy” rating but set a $91 price target, below recent trading levels, signaling limited near-term upside in that analyst’s view. BTIG Reaffirms Medtronic Buy Rating Medtronic Stock Up 1.8% MDT stock opened at $92.22 on Wednesday. The stock has a market capitalization of $118.04 billion, a PE ratio of 24.72, a price-to-earnings-growth ratio of 2.45 and a beta of 0.55. Medtronic PLC has a 52 week low of $73.31 and a 52 week high of $106.33. The company has a quick ratio of 1.62, a current ratio of 2.13 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average of $83.60 and a 200 day moving average of $86.13. Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The business had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. Medtronic’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.62 EPS. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.94 earnings per share for the current year.
Medtronic Increases Dividend The company also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were given a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s payout ratio is currently 77.21%.
Wall Street Analyst Weigh In Several research analysts recently commented on the stock. Royal Bank Of Canada reiterated an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Rothschild & Co Redburn lowered their target price on shares of Medtronic from $111.00 to $106.00 and set a “buy” rating for the company in a research note on Friday, June 5th. Weiss Ratings lowered shares of Medtronic from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday, May 21st. Mizuho reduced their price target on Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research report on Wednesday, June 3rd. Finally, BTIG Research reiterated a “buy” rating and set a $91.00 price objective on shares of Medtronic in a report on Tuesday. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus target price of $98.83.
Read Our Latest Stock Report on Medtronic
Insider Activity In related news, EVP Harry Skip Kiil sold 4,189 shares of the firm’s stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the transaction, the executive vice president owned 37,227 shares in the company, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.26% of the stock is currently owned by insiders.
Medtronic Company Profile (Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Recommended Stories Five stocks we like better than Medtronic The AI Boom Is Turning This Cable Maker Into a Stock to Watch A Star Investor Just Trimmed Amazon—Here’s What It means Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look Home Depot Analysts See a Path to $375 and Beyond Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
Asset Management One ve 2. čtvrtletí snížila podíl v Medtronic o 3,9 % na 563 263 akcií v hodnotě 44,064 mil. USD. Medtronic zároveň oznámil čtvrtletní EPS 1,55 USD a tržby 9,81 mld. USD.
Asset Management One Co. Ltd. lowered its stake in Medtronic PLC (NYSE:MDT – Free Report) by 3.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 563,263 shares of the medical technology company’s stock after selling 22,946 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Medtronic were worth $44,064,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Anfield Capital Management LLC increased its holdings in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Monetary Solutions Ltd bought a new position in shares of Medtronic during the 4th quarter valued at approximately $27,000. Acumen Wealth Advisors LLC purchased a new position in shares of Medtronic in the fourth quarter valued at $29,000. Imprint Wealth LLC purchased a new position in shares of Medtronic in the third quarter valued at $31,000. Finally, Basepoint Wealth LLC bought a new stake in Medtronic in the fourth quarter worth $32,000. Institutional investors own 82.06% of the company’s stock.
Analysts Set New Price Targets MDT has been the topic of a number of recent research reports. Wells Fargo & Company decreased their price target on shares of Medtronic from $114.00 to $102.00 and set an “overweight” rating on the stock in a research note on Thursday, June 4th. Rothschild & Co Redburn reduced their price objective on Medtronic from $111.00 to $106.00 and set a “buy” rating on the stock in a research note on Friday, June 5th. Deutsche Bank Aktiengesellschaft dropped their target price on Medtronic from $100.00 to $78.00 and set a “hold” rating for the company in a report on Thursday, June 4th. Mizuho lowered their price target on Medtronic from $120.00 to $100.00 and set an “outperform” rating for the company in a research report on Wednesday, June 3rd. Finally, TD Cowen lowered their price target on Medtronic from $119.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, July 10th. Eighteen research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $98.83.
Get Our Latest Analysis on MDT
Medtronic Stock Down 0.1% Shares of NYSE:MDT opened at $90.69 on Friday. The business has a 50 day simple moving average of $83.01 and a two-hundred day simple moving average of $86.33. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm has a market capitalization of $116.09 billion, a PE ratio of 24.31, a price-to-earnings-growth ratio of 2.43 and a beta of 0.55.
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to the consensus estimate of $9.62 billion. During the same quarter in the prior year, the company posted $1.62 EPS. Medtronic’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, equities analysts predict that Medtronic PLC will post 5.94 EPS for the current year.
Medtronic Increases Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.
Insider Transactions at Medtronic In other Medtronic news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the completion of the sale, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is currently owned by company insiders.
Medtronic Company Profile (Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Featured Stories Five stocks we like better than Medtronic Asian Market Circuit Breakers Hit Stocks, Not AI Demand Riot Platforms Re-Wires the Ledger for a $9B AI Power Play Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy? Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEPublic Storage $PSA Shares Purchased by Asset Management One Co. Ltd.
First Bank & Trust purchased a new stake in Medtronic PLC (NYSE:MDT – Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 24,967 shares of the medical technology company’s stock, valued at approximately $1,953,000.
Several other institutional investors also recently made changes to their positions in the stock. Curbstone Financial Management Corp raised its position in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company’s stock worth $537,000 after buying an additional 100 shares during the period. New England Capital Financial Advisors LLC boosted its holdings in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company’s stock valued at $135,000 after acquiring an additional 101 shares during the last quarter. Ipsen Advisor Group LLC grew its position in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company’s stock valued at $572,000 after acquiring an additional 101 shares during the period. Quadrant Capital Group LLC grew its position in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company’s stock valued at $3,120,000 after acquiring an additional 101 shares during the period. Finally, Rossby Financial LCC increased its stake in Medtronic by 5.1% during the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company’s stock worth $211,000 after acquiring an additional 107 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades A number of equities analysts have recently commented on the company. Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Monday. BTIG Research reiterated a “buy” rating and set a $91.00 target price on shares of Medtronic in a report on Monday, July 13th. Royal Bank Of Canada reissued an “outperform” rating and set a $118.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Sanford C. Bernstein cut their price target on shares of Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a report on Thursday, June 4th. Finally, Mizuho cut their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Wednesday, June 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Medtronic has an average rating of “Moderate Buy” and an average target price of $98.83.
Read Our Latest Analysis on Medtronic
Key Stories Impacting Medtronic Here are the key news stories impacting Medtronic this week:
Positive Sentiment: UBS upgraded Medtronic to Buy from Neutral, describing a “turnaround” underway at the company. The upgrade suggests improving execution and renewed confidence in Medtronic’s ability to return to sustainable growth. Is Medtronic Becoming a Turnaround Story? Positive Sentiment: Medtronic is being promoted as an undervalued dividend-growth company, which may attract income-focused investors if the market begins to recognize potential for operational improvement and valuation expansion. Medtronic: Buy This Undervalued Dividend Aristocrat Positive Sentiment: Medtronic’s collaboration with Orchestra BioMed is progressing: the BACKBEAT pivotal trial remains on track to reach its enrollment target by the end of the third quarter of 2026, with primary data expected in the second quarter of 2027. Successful results could support future device-related growth. Orchestra BioMed Reports Second Quarter 2026 Results Neutral Sentiment: Recent coverage highlights Medtronic’s appeal relative to Johnson & Johnson and Abbott, but portrays the company more as a turnaround and valuation opportunity than a consistent high-growth story. Investors may continue to favor peers with stronger near-term organic growth. Johnson & Johnson vs. Medtronic Abbott vs. Medtronic Insider Buying and Selling In related news, EVP Harry Skip Kiil sold 4,189 shares of the business’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.26% of the company’s stock.
Medtronic Stock Up 2.5% Shares of NYSE MDT opened at $89.31 on Tuesday. The stock has a fifty day moving average price of $82.25 and a 200 day moving average price of $86.55. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a market cap of $114.32 billion, a P/E ratio of 23.94, a P/E/G ratio of 2.34 and a beta of 0.55.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The firm’s quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.
Medtronic Increases Dividend The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. The ex-dividend date was Friday, June 26th. This is an increase from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is 77.21%.
Medtronic Profile (Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Read More Five stocks we like better than Medtronic SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat 3 Dividend Champion Utilities for a Market That Can’t Sit Still These 3 Most-Upgraded Stocks Have Almost Nothing to Do With AI First Solar’s Profit Engine Faces a New Policy Test in Washington
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEFocus Financial Network Inc. Has $4.21 Million Stake in Taiwan Semiconductor Manufacturing Company Ltd. $TSM
NEXT HEADLINE »Compound Planning Inc. Sells 7,044 Shares of Microsoft Corporation $MSFT
Medtronic ve 4. čtvrtletí fiskálního roku 2026 zvýšil tržby o 9,9 % na 9,8 miliardy USD, ale upravený EPS klesl o 4,3 % na 1,55 USD a výhled zklamal. Intuitive Surgical naopak ve 2. čtvrtletí zvýšil tržby o 19 % na 2,89 miliardy USD a upravený EPS o 28 % na 2,80 USD.
Medtronic (MDT +1.44%) and Intuitive Surgical (ISRG +1.36%), two medical device leaders, haven't performed well this year. While weakness in the broader healthcare sector hasn't helped, they have both encountered company-specific issues that have contributed to their lagging the market. The good news is that there are solid reasons to think they can bounce back, but which one should investors consider right now?
Image source: Getty Images.
What's going on with Medtronic? Medtronic has many qualities: A large medical device business with dozens of products across several therapeutic areas. The company has a deep footprint in the healthcare sector, a strong reputation, and it records consistent revenue and earnings. However, its most recent financial results have been mixed. In the fourth quarter of its fiscal year 2026, which ended on April 24, Medtronic's revenue increased by 9.9% to $9.8 billion. The company's adjusted earnings per share (EPS) were $1.55, a 4.3% decline due to higher costs from multiple sources, including tariffs.
Worse, the company's guidance for the next fiscal year fell short of analysts' expectations, sending the stock lower following its earnings release. Still, there are several things to be excited about. Medtronic posted its highest annual revenue growth in a decade during its last fiscal year.
Today's Change
(
1.44
%) $
1.24
Current Price
$
87.16
It has addressed some of the top-line growth concerns investors had, partly thanks to its Pulse Field Ablation franchise. Further, the company launched new products that should eventually contribute to sales growth. Last year, Medtronic announced that the U.S. Food and Drug Administration had cleared its Hugo robotic-assisted surgery (RAS) system for urologic procedures, putting it in direct competition with Intuitive Surgical.
The RAS market is underpenetrated, and as Medtronic earns more indications for the Hugo system, it should eventually meaningfully impact its financial results. We could also see improved margins once it completes the spin-off of its lower-margin diabetes care division. Lastly, Medtronic is a phenomenal dividend stock, offering a forward yield of 3.4% and having increased its payouts for 49 consecutive years. It is a great pick for income-seeking investors.
Can Intuitive Surgical overcome its challenges? Intuitive Surgical is dealing with tariffs, increased competition from Medtronic and Johnson & Johnson (JNJ +0.88%), and lower margins associated with its latest launch, the da Vinci 5 surgical system. The company's financial results look strong regardless. In the second quarter, Intuitive Surgical's revenue increased by 19% year over year to $2.89 billion, while its adjusted EPS came in at $2.80, 28% higher than the year-ago period. But many investors are wondering whether they should pay a premium for a company with growing challenges, including competition.
Today's Change
(
1.36
%) $
5.10
Current Price
$
378.81
Intuitive Surgical trades at 34.1x forward earnings, well above the 18.5x average for healthcare stocks. Still, there are reasons to be optimistic. Intuitive Surgical's da Vinci 5 will continue to earn additional indications. Given its greater computing power than previous versions, and built-in architecture for data analytics and AI-powered features, this new machine may significantly expand the RAS market.
It is already boosting Intuitive Surgical's installed base. The more devices it places, the more recurring revenue the company generates from instruments and accessories. The da Vinci 5's innovative features can also help Intuitive Surgical stay ahead of the competition, and that's before we mention the company's massive lead in this area. It launched its first RAS device more than 25 years ago and has built a reputation ever since. All of those factors put Intuitive Surgical in a strong position to capitalize on the growing RAS industry.
Medtronic is trading at 14.3x forward earnings. Its lower multiple makes sense, considering Intuitive Surgical typically grows its revenue and earnings faster. The market is valuing these two differently because they are different. One is a mature, consistent business with fairly low revenue and earnings growth, while the other is arguably still in the growth stage. Also, one pays a dividend -- and boasts an impressive streak of consecutive payout growth -- and the other one doesn't.
In other words, these two stocks will appeal to investors with different goals. Those looking for reliable income payers should opt for Medtronic. The company will be the less volatile of the two moving forward and could help stabilize a well-diversified portfolio during challenging times. Growth-oriented investors might want to pick Intuitive Surgical. They should expect bigger price swings, but Intuitive will likely deliver stronger returns over the long run.
180 Wealth Advisors LLC decreased its holdings in shares of Medtronic PLC (NYSE:MDT – Free Report) by 75.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,951 shares of the medical technology company’s stock after selling 29,822 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Medtronic were worth $778,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDT. Monetary Solutions Ltd purchased a new position in shares of Medtronic during the 4th quarter worth $27,000. Anfield Capital Management LLC increased its position in shares of Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 230 shares during the last quarter. Acumen Wealth Advisors LLC purchased a new stake in Medtronic in the 4th quarter valued at about $29,000. Imprint Wealth LLC purchased a new stake in Medtronic in the 3rd quarter valued at about $31,000. Finally, Basepoint Wealth LLC purchased a new stake in Medtronic in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.
Medtronic Stock Down 0.1% Shares of NYSE:MDT opened at $85.92 on Friday. The firm has a market capitalization of $109.98 billion, a PE ratio of 23.03, a price-to-earnings-growth ratio of 2.31 and a beta of 0.55. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The firm’s 50-day moving average is $81.68 and its two-hundred day moving average is $86.68.
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a net margin of 13.20% and a return on equity of 14.51%. The firm had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. During the same quarter in the previous year, the business posted $1.62 earnings per share. The business’s quarterly revenue was up 9.9% compared to the same quarter last year. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Analysts predict that Medtronic PLC will post 5.94 EPS for the current year.
Medtronic Increases Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were given a dividend of $0.72 per share. This is an increase from Medtronic’s previous quarterly dividend of $0.71. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.4%. The ex-dividend date of this dividend was Friday, June 26th. Medtronic’s dividend payout ratio is currently 77.21%.
Analysts Set New Price Targets Several research analysts have weighed in on the stock. The Goldman Sachs Group lowered their target price on shares of Medtronic from $84.00 to $83.00 and set a “neutral” rating for the company in a research note on Thursday, June 4th. Mizuho reduced their price target on shares of Medtronic from $120.00 to $100.00 and set an “outperform” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC restated a “buy” rating and issued a $101.00 price objective on shares of Medtronic in a report on Wednesday, June 17th. BTIG Research reaffirmed a “buy” rating and set a $91.00 price objective on shares of Medtronic in a research report on Monday, July 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a report on Thursday, June 4th. Eighteen research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.83.
Read Our Latest Report on Medtronic
Medtronic News Roundup Here are the key news stories impacting Medtronic this week:
Positive Sentiment: Medtronic received an expanded CE Mark indication in Europe for its Affera™ Mapping and Ablation System and Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia and premature ventricular complexes. The approval expands the addressable market for the company’s cardiac-ablation technology and supports its international growth strategy. U.S. pivotal-trial enrollment is also underway. Medtronic announces expanded CE Mark indication for Affera and Sphere-9 Positive Sentiment: A bullish investment opinion argues that Medtronic’s medical-device portfolio and long-term growth prospects could support substantial appreciation through the end of 2026. This is an analyst-style opinion rather than a new company announcement, so its effect is likely limited. Medtronic could soar by 40 percent Neutral Sentiment: Medtronic recently exceeded quarterly revenue and adjusted-EPS expectations, reporting $9.81 billion in revenue and $1.55 in EPS. Revenue increased 9.9% year over year, while full-year fiscal 2027 EPS guidance remains $5.90 to $6.00. These results provide a constructive operating backdrop but do not eliminate litigation concerns. Negative Sentiment: A U.S. jury ordered Medtronic to pay $88 million in the first trial involving allegations related to Covidien hernia mesh. Although the award may be manageable relative to Medtronic’s size, the verdict could raise concerns about additional lawsuits, settlement costs and potential reputational damage. Jury says Medtronic owes 88 million dollars in hernia mesh case Insider Buying and Selling at Medtronic In other news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president directly owned 37,227 shares in the company, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.26% of the company’s stock.
Medtronic Profile (Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
Further Reading Five stocks we like better than Medtronic Sandisk Just Delivered a Blowout Quarter—Here’s Why the Stock Is Falling 4 Oil and Gas ETF Plays as Prices Stay Sky-High What Tesla Stands to Lose If It Walks Away From China Disney Sets Up for a Magical Year in 2027
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEClark Asset Management LLC Purchases 42,555 Shares of Vanguard Value ETF $VTV
NEXT HEADLINE »Vanguard Growth ETF $VUG Holdings Lifted by Clark Asset Management LLC
Medtronic získal rozšířené značení CE pro systém Affera se sondou Sphere-9 k léčbě komorových arytmií včetně komorové tachykardie a PVC. FDA zároveň udělil sondě označení Breakthrough Device Designation.
Sphere-9 all-in-one mapping and ablation, large-tip focal, dual energy catheter first to be CE Marked for ventricular ablation
New indication marks important milestone for ventricular arrhythmia patients as positive physician sentiment and global expansion for Sphere‑9 continue
Sphere VT U.S. pivotal trial enrollment underway
, /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced an expanded CE Mark indication for the Affera™ Mapping and Ablation System with Sphere-9™ Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular complexes (PVCs). The Sphere-9 catheter is the first all-in-one mapping and ablation, large-tip focal, dual-energy catheter CE marked for ventricular ablation.
"This milestone is a major step forward as we continue to expand the footprint of the Affera technology to more physicians and patients," said Rebecca Seidel, president of the Electrophysiology Therapies business at Medtronic. "Indication expansion to include ventricular arrhythmias unlocks another fast-growing market opportunity to keep building on our momentum, powered by the versatility, safety and efficiency of the Sphere-9 catheter."
Additionally, in recognition of the critical unmet need for ventricular arrhythmia treatments, the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation for the Sphere-9 catheter for the treatment of ventricular arrhythmias, which provides an expedited regulatory pathway for the technology in this patient population. The Sphere VT pivotal trial to evaluate Sphere-9 for the treatment of VT and support future approval in the US is now enrolling patients.
The Affera Mapping and Ablation System with Sphere-9 Catheter is an all-in-one, dual-energy pulsed field (PF) and radiofrequency (RF) ablation and high-definition mapping catheter for use in cardiac ablation procedures.
"Physicians have long needed better tools for ventricular arrhythmias, and we're proud to deliver a technology that addresses this unmet need and moves the needle on patient care," said Khaldoun Tarakji, M.D., MPH, vice president, chief medical officer, Cardiac Ablation Solutions business, which is part of the Cardiovascular Portfolio at Medtronic. "The unique features of Sphere-9, including a single catheter to map and ablate using radiofrequency or pulsed field energy and a large footprint, make it an excellent tool for a variety of arrhythmias, including those that may be challenging to treat."
About Ventricular Arrhythmias
VT is a potentially life-threatening arrhythmia that causes the heart to beat abnormally fast.1 Unlike atrial fibrillation, VT affects the lower chamber of the heart and often presents after a heart attack or together with other advanced heart diseases.1,2 VT patients are often treated with medications and may receive life-saving therapies from implanted defibrillators in the form of pacing or shocks.1 Catheter ablation for VT is an established treatment option, but outcomes have remained suboptimal2 with little ablation tool innovation in recent years. As a result, a significant unmet need exists to improve patient care.3
PVCs are extra or early heartbeats that start in the heart's lower chambers (ventricles), briefly disrupting normal rhythm and potentially causing a flutter-like feeling in the chest.4
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit Medtronic.com and follow @Medtronic on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Sciria,C. et al. Trends and Outcomes of Catheter Ablation of Ventricular Tachycardia in Patients With Ischemic and Nonischemic Cardiomyopathy. Circ: Arr. and Elec. 2022; vol.15, no. 4. 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias. Cheung, J, et al. Outcomes, Costs, and 30-Day Readmissions After Catheter Ablation of Myocardial Infarct–Associated Ventricular Tachycardia in the Real World: Nationwide Readmissions Database 2010 to 2015. Circ: Arr. and Elec. 2018; vol. 11, issue 11. American Heart Association, "Premature Contractions: PACs and PVCs." https://www.heart.org/en/health-topics/arrhythmia/about-arrhythmia/premature-contractions-pacs-and-pvcs Contacts:
Leslie Williamson
Public Relations
+1-612-227-5099
Ingrid Goldberg
Investor Relations
+1-763-505-2696
Andra AP fonden lowered its stake in Medtronic PLC (NYSE:MDT – Free Report) by 3.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 253,329 shares of the medical technology company’s stock after selling 10,400 shares during the quarter. Andra AP fonden’s holdings in Medtronic were worth $21,951,000 at the end of the most recent quarter.
Several other large investors have also recently made changes to their positions in MDT. Madison Asset Management LLC lifted its stake in Medtronic by 25.0% during the 1st quarter. Madison Asset Management LLC now owns 244,000 shares of the medical technology company’s stock worth $21,143,000 after acquiring an additional 48,784 shares in the last quarter. Convergence Investment Partners LLC grew its position in Medtronic by 82.8% in the 1st quarter. Convergence Investment Partners LLC now owns 46,789 shares of the medical technology company’s stock valued at $4,054,000 after acquiring an additional 21,196 shares in the last quarter. Commerzbank Aktiengesellschaft FI increased its stake in Medtronic by 9.0% during the first quarter. Commerzbank Aktiengesellschaft FI now owns 46,929 shares of the medical technology company’s stock worth $4,066,000 after purchasing an additional 3,879 shares during the period. Florida Financial Advisors LLC lifted its position in shares of Medtronic by 16.2% during the first quarter. Florida Financial Advisors LLC now owns 3,328 shares of the medical technology company’s stock worth $288,000 after purchasing an additional 465 shares in the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. boosted its stake in shares of Medtronic by 1.4% in the first quarter. Leith Wheeler Investment Counsel Ltd. now owns 323,384 shares of the medical technology company’s stock valued at $28,021,000 after purchasing an additional 4,540 shares during the period. 82.06% of the stock is currently owned by institutional investors and hedge funds.
Medtronic Stock Up 0.1% Medtronic stock opened at $83.29 on Tuesday. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.13 and a quick ratio of 1.62. The stock has a market cap of $106.61 billion, a PE ratio of 22.33, a P/E/G ratio of 2.23 and a beta of 0.56. The stock’s fifty day moving average is $79.68 and its two-hundred day moving average is $87.84.
Medtronic (NYSE:MDT – Get Free Report) last announced its quarterly earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion during the quarter, compared to the consensus estimate of $9.62 billion. During the same period in the previous year, the business earned $1.62 EPS. Medtronic’s revenue for the quarter was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, sell-side analysts expect that Medtronic PLC will post 5.94 EPS for the current fiscal year.
Medtronic Increases Dividend The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Stockholders of record on Friday, June 26th were issued a $0.72 dividend. This represents a $2.88 annualized dividend and a dividend yield of 3.5%. The ex-dividend date was Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio (DPR) is currently 77.21%.
Insider Activity In related news, EVP Harry Skip Kiil sold 4,189 shares of the stock in a transaction on Monday, June 8th. The shares were sold at an average price of $80.44, for a total value of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company’s stock, valued at $2,994,539.88. This trade represents a 10.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.26% of the company’s stock.
Wall Street Analyst Weigh In Several brokerages recently weighed in on MDT. Barclays upped their target price on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada restated an “outperform” rating and issued a $118.00 price target on shares of Medtronic in a research note on Thursday, June 4th. Argus cut their price objective on Medtronic from $125.00 to $115.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. The Goldman Sachs Group reduced their price objective on Medtronic from $84.00 to $83.00 and set a “neutral” rating on the stock in a research note on Thursday, June 4th. Finally, Piper Sandler reiterated a “neutral” rating and issued a $85.00 target price on shares of Medtronic in a report on Tuesday, June 16th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and a consensus target price of $98.21.
Read Our Latest Research Report on Medtronic
Medtronic Company Profile (Free Report)
Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.
Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).
See Also Five stocks we like better than Medtronic The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
« PREVIOUS HEADLINEAndra AP fonden Purchases 53,990 Shares of Thermo Fisher Scientific Inc. $TMO
NEXT HEADLINE »Andra AP fonden Has $24.38 Million Holdings in Incyte Corporation $INCY
Medtronic dokončila akvizici SPR Therapeutics za 650 milionů USD a rozšířila portfolio léčby bolesti o technologii SPRINT PNS. Cílí na minimálně invazivní, neopioidní léčbu chronické i akutní bolesti.
Acquisition adds category-defining SPRINT® PNS technology to Medtronic's pain therapy portfolio—the broadest in the industry.¹
, /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management. The acquisition is valued at $650 million, consisting of an upfront cash payment.
Chronic pain affects nearly 50 million U.S. adults2, and for some, it can significantly impact their mobility, sleep quality, work performance, and overall quality of life. PNS is a form of neuromodulation that delivers mild electrical stimulation near targeted peripheral nerves to help reduce pain. As a non-opioid and non-surgical therapy, PNS can expand pain management treatment options, support earlier intervention in the care continuum, and help create additional opportunities for individualized patient care.
SPR's FDA-cleared SPRINT® PNS System is a short-term therapy designed to provide pain relief using a 60-day, minimally invasive treatment approach that does not require a permanent implant. SPRINT® is supported by a growing body of clinical research, including multiple prospective clinical studies, case series, and multi-center randomized controlled trials. Pooled results from 13 studies show that 60% of patients achieved meaningful pain relief (≥50% reduction in pain intensity) at the end of the 60-day treatment completion, with responders experiencing an average 76% reduction in pain intensity. Across all patients, there was a 56% reduction in pain intensity.3
"Medtronic is committed to expanding access to innovative therapies that can meaningfully improve patient lives," said Domenico De Paolis, Interim President of the Neuromodulation Operating Unit, part of the Medtronic Neuroscience Portfolio. "The addition of SPRINT® extends our ability to serve patients across the continuum of pain care and broadens patient access to a minimally invasive treatment option to address both chronic and acute pain."
"At SPR, our mission has always been to help people living with pain reclaim their lives," said Maria Bennett, President, Founder, and Chief Executive Officer of SPR. "We are proud of the impact our team has made in advancing innovative therapies that offer meaningful pain relief. Joining Medtronic enables us to build on that foundation, expand access to our technology, and serve more patients living with pain."
This acquisition reflects Medtronic's continued focus on strategic deals that strengthen its leadership across core businesses. It is expected to be minimally dilutive to Medtronic adjusted EPS in FY27 and neutral to accretive thereafter. The company remains committed to pursuing high-growth opportunities that complement its portfolio and enhance therapy options for physicians and hospital partners.
About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission – to alleviate pain, restore health, and extend life – unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit medtronic.com and follow us on LinkedIn.
About SPR
SPR is a medical technology company focused on advancing minimally invasive therapies for the treatment of pain. Its SPRINT® PNS System is designed to deliver short-term peripheral nerve stimulation therapy for sustained pain relief of up to three months following treatment and is supported by a growing body of clinical evidence and expanding reimbursement coverage. For more information on SPR Therapeutics, visit sprpainrelief.com and follow SPR on LinkedIn.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Medtronic Contacts:
Justin Paquette
Ingrid Goldberg
Public Relations
Investor Relations
+1-612-271-7935
[email protected]
References
Medtronic SCS Value Summary FY25; Lo Bianco, G., et al. (2025). Barriers to neuromodulation. J Anesth Analg Crit Care, 5(1):3. Lucas JW, Sohi I. Chronic pain and high-impact chronic pain in U.S. adults, 2023. NCHS Data Brief, no 518. Hyattsville, MD: National Center for Health Statistics. 2024. DOI: https://dx.doi.org/10.15620/cdc/169630. SPR SPRINT® PNS System Indications for Use. SPR Pain Relief. Accessed July 2, 2026. https://www.sprpainrelief.com/indications SOURCE Medtronic plc
Medtronic ve 4. čtvrtletí překonal odhady díky tržbám 9,81 miliardy USD a zvýšil výhled na fiskální rok 2027. Akcie od poslední výsledkové zprávy přidaly asi 1,5 %.
It has been about a month since the last earnings report for Medtronic (MDT - Free Report) . Shares have added about 1.5% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Medtronic due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Medtronic's Q4 Earnings & Revenues Top EstimatesMedtronic plc posted fourth-quarter fiscal 2026 adjusted earnings of $1.55 per share, down 4.3% from the year-ago quarter but above the Zacks Consensus Estimate by 0.6%.
For the full-year fiscal 2026, adjusted earnings per share was $5.53, up 0.7% year over year. The figure missed the Zacks Consensus Estimate by 0.2%.
Revenue rose 9.9% year over year to $9.81 billion and beat the consensus by 1.5%. The upside came as procedure-driven demand stayed firm across key franchises. Cardiac Ablation Solutions revenue surged 78% globally, including 124% growth in the United States, while multiple portfolios delivered healthy gains.
Full-year worldwide revenues totaled $36.4 billion, up 8.4% year over year. The top line marginally surpassed the Zacks Consensus Estimate by 0.6%.
MDT’s Portfolio Mix Tilted Toward Cardiovascular
Cardiovascular generated $3.80 billion in the quarter, underscoring the importance of the company’s largest portfolio to overall momentum. Neuroscience contributed $2.75 billion, and Medical Surgical added $2.39 billion, reflecting steady demand across hospital-based therapy areas.
Diabetes produced $837 million of revenue and remained a meaningful growth lever alongside the broader portfolios. The mix shows Medtronic’s exposure to both large, recurring procedural categories and faster-moving product cycles in areas like diabetes management.
MDT’s Geographic Split Favored International Growth
U.S. revenue increased 7.1% year over year to $4.87 billion, supported by gains across major portfolios and continued procedure volume resilience.
International revenue advanced 12.8% to $4.94 billion. The overseas outperformance was broad-based and included a notable lift in Diabetes internationally, reinforcing how global scale can amplify Medtronic’s reported results when demand is healthy.
Medtronic’s Adjusted Margins Mixed in the Quarter
On an adjusted basis, Medtronic posted gross margin of 65.4% in fourth-quarter fiscal 2026, up 30 basis points year over year, reflecting a modest improvement in profitability at the product level.
However, operating leverage moved the other way. The adjusted operating margin fell to 25.5%, down 230 basis points from the prior-year quarter, as the company absorbed notable headwinds, including margin impacts tied to the MiniMed Blackstone payment and tariffs.
Medtronic’s Cash Generation Supports Returns and Investment
Operating cash flow totaled $7.33 billion in fiscal 2026, providing the financial flexibility to fund both portfolio investment and shareholder distributions. Free cash flow was $5.43 billion for the year, equal to 76% free cash flow conversion from adjusted net earnings.
Medtronic also returned $4.2 billion to shareholders in fiscal 2026 and ended the year with $9.2 billion in cash and investments.
Medtronic’s FY27 Guidance and Shareholder Returns
Looking ahead, the company guided for fiscal 2027 organic revenue growth of 6.75% to 7.25% and adjusted earnings of $5.90 to $6.00 per share. The outlook bakes in the benefit of a 53rd week, additional M&A and a full-year contribution from the Diabetes business, while also considering tariffs, interest and tax expense. The Zacks Consensus Estimate projects fiscal 2027 revenues of $38.39 billion, up 6.1% from fiscal 2026 levels, while earnings per share is expected to rise 9.7% to $6.08.
Medtronic also increased its quarterly dividend to $0.72 per share, implying an annual rate of $2.88 and marking its 49th consecutive year of dividend increases.
How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a upward trend in estimates revision.
VGM ScoresCurrently, Medtronic has a subpar Growth Score of D, though it is lagging a bit on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for value investors.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Interestingly, Medtronic has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months.
Globus Medical za poslední rok vzrostl o 46,1 % a analytici mu dávají vyšší cílovou cenu než Medtronic. Firma navíc v prvním čtvrtletí zvýšila tržby o 27 % meziročně.
Key Takeaways Globus Medical outpaced Medtronic in share gains and analyst price target upside over the past year. GMED posted strong Spine and Trauma growth, stayed debt-free and continued investing in R&D and new product. MDT expanded robotics and digital surgery, increased its dividend and returned $4.2 billion to shareholders. Over the past year, shares of Globus Medical (GMED - Free Report) and Medtronic (MDT - Free Report) have gained 46.1% and 7.6%, respectively, significantly outperforming the industry’s 9.6% decline. U.S. medical stocks offer strong structural growth prospects driven by an aging global population, rising chronic disease prevalence and rapid technological integration.
Given these positives, Globus Medical posted revenue growth of 27% year over year in the first quarter. Medtronic experienced 9.9% year-over-year revenue growth in the fiscal fourth quarter.
It is time for investors to assess whether this momentum can extend through 2026. Let’s find out.
Image Source: Zacks Investment Research
The Case for GMEDGlobus Medical is taking share in Musculoskeletal Solutions, supported by broad-based growth across its core categories. In the first quarter of 2026, U.S. Spine marked its third straight quarter of 10% growth, with double-digit growth cited across standard fixation, minimally invasive surgery pedicle screws, expandable transforaminal lumbar interbody fusion, anteriorlumbar interbody fusion, posterior cervical and cervical plating.
International Spine also grew 16.4% in the first quarter. Trauma revenues increased 30.4%, aided by continued adoption of the core trauma line and the Precice limb lengthening portfolio, with ANTHEM Elbow continuing to exceed expectations.
The company continues to invest in R&D and product cadence as core part of its competitive positioning. In the first quarter of 2026, R&D expenses were 4.8% of sales, with management expecting it to be 5-6% of net sales for the full year, with spend ramping methodically through the year as product efforts progress.
Its early FDA 510(k) clearances for patient-specific lumbar spacers and rods reinforced its roadmap of linking planning software, enabling technologies and implants into one workflow. This launch activity complements the broader post-merger strategy of compressing development timelines and keeping the portfolio fresh across spine and orthopedics.
Globus Medical ended the first quarter of 2026 with $560.9 million of cash and cash equivalents and $68.9 million of short-term marketable securities. The company remains debt-free, which preserves the capacity to fund R&D, sales-force investments and manufacturing expansion without relying on external financing. Liquidity is also being replenished internally, with $202.4 million of operating cash flow generated in the quarter. This supports continued capital spending and buybacks alongside ongoing integration work.
The Case for MDTWithin Medtronic’s Medical Surgical portfolio, growth is supported by Hugo robotic-assisted surgery, Touch Surgery, Endoscopy and Acute Care & Monitoring. Surgical & Endoscopy rose 3.5% organically in the fourth quarter, with Hugo contributing as procedure volumes expanded globally.
Acute Care & Monitoring grew 10.5% organically in the fourth quarter, driven by Nellcor pulse oximetry, respiratory and airway products, and perioperative offerings. Management expects MedSurg growth to normalize in fiscal 2027, but the portfolio enters the year with broader robotics and digital capabilities.
Also, the company submitted Hugo to the FDA for general surgery and gynecologic indications, as well as for the LigaSure RAS vessel sealer. It received FDA clearance for ProGrip Advanced, a mesh optimized for robotic-assisted ventral hernia repair. Touch Surgery installations exceeded 1,400 and increased more than 30% sequentially, adding a digital layer to the robotics ecosystem.
Medtronic exited fiscal 2026 with $9.2 billion in cash and investments compared with $8.38 billion at the end of the fiscal third quarter. On the debt side, the company issued $1.75 billion of long-term debt and repaid $2.93 billion during fiscal 2026, while current debt obligations increased $9 million on a net basis.
Medtronic returned $4.2 billion to shareholders in fiscal 2026 and raised its quarterly dividend to $0.72 per share for the first quarter of fiscal 2027, marking the 49th consecutive year of dividend increases. The balance sheet position gives the company room to support tuck-in deals in coronary, neurovascular, neuromodulation and EP imaging while maintaining shareholder returns.
Valuation: GMED vs. MDTGlobus Medical currently trades at a forward, one-year, price-to-sales (P/S) of 3.55X, higher than its median. Medtronic’s 2.67X P/S sits below its median. Additionally, Globus Medical trades expensive than Medtronic.
Image Source: Zacks Investment Research
Short Term Price Target Favors GMED Over MDTGMED: Based on short-term price targets offered by 12 analysts, the average price target of $109.83 represents an increase of 29.75% from the last closing price.
Image Source: Zacks Investment Research
MDT: Based on short-term price targets offered by 25 analysts, the average price target of $96.96 represents an increase of 20.42% from the last closing price.
Image Source: Zacks Investment Research
End NoteBoth Globus Medical and Medtronic are well positioned to benefit from long-term growth trends in musculoskeletal and medical technology markets, but they offer different investment profiles.
Globus Medical stands out for its strong execution in Spine and Trauma, robust product innovation pipeline, debt-free balance sheet and disciplined investment in R&D, positioning it as a higher-growth company. Meanwhile, Medtronic benefits from greater scale and a diversified portfolio, supported by expanding robotic-assisted surgery capabilities, digital surgery platforms and a long track record of shareholder returns through dividends and capital allocation.
For investors, Globus Medical, currently carrying a Zacks Rank #2 (Buy), appears to be the stronger choice, given that it has outperformed Medtronic over the past year. However, for investors seeking a more discounted entry, Medtronic, carrying a Zacks Rank #4 (Sell) at present, may offer deeper value but with meaningfully higher risk. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
